Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 4, 2009, Pages 419-426

  Saussoy, Pascale ^a   Vaerman, Jean Luc ^a   Druez, Vincent ^b   Deneys, Véronique ^c   Straetmans, Nicole ^d   Cornu, Guy ^a   Ferrant, Augustin ^a   Latinne, Dominique ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Institut de Médecine de Traumatologie et de Réadaptation   (Belgium)

^c Service du Sang   (Belgium)

^d Hospital de Jolimont   (Belgium)

Author keywords

Bone marrow; Immunophenotyping; Lineage marker; Real time PCR; Reference values

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD3E ANTIGEN; CD79A ANTIGEN; MESSENGER RNA; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CELL SELECTION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE;

ADOLESCENT; ADULT; BONE MARROW CELLS; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTH; HUMANS; LEUKEMIA; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 63849290499     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.093     Document Type: Article

References (37)

1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
2. Garand R, Bene MC. A new approach of acute lymphoblastic leukemia immunophenotypic classification: 1984-1994 the GEIL experience. Groupe d'Etude Immunologique des Leucemies. Leuk Lymphoma 1994;13(Suppl 1): 1-5.
3. Kern W, Kohlmann A, Schoch C, Schnittger S, Haferlach T. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. Cancer 2006;107:2401-7.
4. Kern W, Kohlmann A, Wuchter C, Schnittger S, Schoch C, Mergenthaler S, et al. Correlation of protein expression and gene expression in acute leukemia. Cytometry B Clin Cytom 2003;55:29-36.
5. Ratei R, Karawajew L, Lacombe F, Jagoda K, Del Poeta G, Kraan J, et al. Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping. Leukemia 2007;21: 1204-11.
6. Saussoy P, Vaerman JL, Straetmans N, Deneys V, Cornu G, Ferrant A, et al. Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs. Clin Chem 2004;50:1165-73.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group. Br J Haematol 1976;33:451-8.
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 1980;44:169-70.
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51: 189-99.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
12. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998;92:596-9.
13. Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 2006;20:620-6.
14. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using'real-time' quantitative reversetranscriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17: 2474-86.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
16. Livak KJ. ABI Prism 7700 sequence detection system. User bulletin 2 1997.
17. Rego EM, Tone LG, Garcia AB, Falcao RP. CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10(qstrong) and CD10(qweak) common acute lymphoblastic leukemia. Leuk Res 1999;23:441-50.
18. Farahat N, Lens D, Zomas A, Morilla R, Matutes E, Catovsky D. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br J Haematol 1995;91:640-6.
19. Farahat N, Morilla A, Owusu-Ankomah K, Morilla R, Pinkerton CR, Treleaven JG, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998;101:158-64.
20. Traweek ST, Liu J, Braziel RM, Johnson RM, Byrnes RK. Detection of myeloperoxidase gene expression in minimally differentiated acute myelogenous leukemia (AMLM0) using in situ hybridization. Diagn Mol Pathol 1995;4:212-9.
21. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000;243:59-75.
22. Abdelhaleem M. Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia. Exp Mol Pathol 2007;83:259-63.
23. Lewis RE, Cruse JM, Sanders CM, Webb RN, Suggs JL. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Mol Pathol 2007;83:462-3.
24. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol 2007;83:471-3.
25. Andrieu V, Radford-Weiss I, Troussard X, Chane C, Valensi F, Guesnu M, et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 1996;92:855-65.
26. Khoury H, Dalal BI, Nevill TJ, Horsman DE, Barnett MJ, Shepherd JD, et al. Acute myelogenous leukemia with t(8;21) - identification of a specific immunophenotype. Leuk Lymphoma 2003;44:1713-8.
27. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470-7.
28. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004;104:4210-8.
29. Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med 2006;130:483-520.
30. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005;106:1189-98.
31. Kern W, Kohlmann A, Schnittger S, Schoch C, Haferlach T. Role of gene expression profiling for diagnosing acute leukemias. Rev Clin Exp Hematol 2005;9:E1.
32. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98:15149-54.
33. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
34. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
35. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck- Verschueren CA, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007;110:3706-14.
36. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550-4.
37. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-85.